FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2160573171> ?p ?o ?g. }

• W2160573171 endingPage "1541" @default.
• W2160573171 startingPage "1534" @default.
• W2160573171 abstract "Background Large granular lymphocyte leukemia is a rare lymphoproliferative disorder associated with autoimmune diseases and impaired hematopoiesis. This study describes the clinical and biological characteristics of 229 patients with T-cell or NK-cell large granular lymphocyte leukemia.Design and Methods The diagnosis was based on a large granular lymphocyte expansion (> 0.5×109/L) lasting more than 6 months. Monoclonal T-cell receptor γ gene rearrangement was detected in all the cases of T-cell large granular lymphocyte leukemia. Patients with chronic NK-cell lymphocytosis had an indolent disease, while those with multiorgan large granular lymphocyte infiltration and an aggressive clinical disease were considered to have NK-cell large granular lymphocyte leukemia.Results The diagnosis of T-cell large granular lymphocyte leukemia was confirmed in 201 cases, chronic NK-cell lymphocytosis in 27 cases and NK-cell large granular lymphocyte leukemia in one case. Associated autoimmune diseases or other neoplasms were present in 74 and 32 cases, respectively. One hundred patients (44%) required treatment, mainly for neutropenia-associated infections (n=45), symptomatic autoimmune diseases (n =24), transfusion-dependant anemia (n=18), and other causes (n=13). Patients were treated with steroids (n= 33), methotrexate (n=62), cytoxan (n=32), or cyclosporine (n=24) either as first-, second-, third- or fourth-line therapy. The overall response rate at 3 months and complete response rate for the various treatments were as follows: steroids (12% and 3%), methotrexate (55% and 21%), cytoxan (66% and 47%), cyclosporine (21% and 4%), respectively. Four out of 13 patients responded to splenectomy. Eleven out of 15 patients responded to cytoxan after methotrexate treatment had failed. The mean number of treatments was 3.4 (range, 1–7). There were 15 large granular lymphocyte leukemia-related deaths.Conclusions Patients with T-cell large granular lymphocyte leukemia and chronic NK-cell lymphocytosis have similar clinical and biological features and responses to treatment. First-line therapy with cytoxan should be tested in a prospective trial." @default.
• W2160573171 created "2016-06-24" @default.
• W2160573171 creator A5014727099 @default.
• W2160573171 creator A5024481322 @default.
• W2160573171 creator A5029042248 @default.
• W2160573171 creator A5036285321 @default.
• W2160573171 creator A5045374333 @default.
• W2160573171 creator A5052071966 @default.
• W2160573171 creator A5055178731 @default.
• W2160573171 creator A5064820449 @default.
• W2160573171 creator A5067324677 @default.
• W2160573171 creator A5081713373 @default.
• W2160573171 creator A5083135231 @default.
• W2160573171 date "2010-04-07" @default.
• W2160573171 modified "2023-10-13" @default.
• W2160573171 title "Analysis of a French cohort of patients with large granular lymphocyte leukemia: a report on 229 cases" @default.
• W2160573171 cites W11411459 @default.
• W2160573171 cites W1480061065 @default.
• W2160573171 cites W153695106 @default.
• W2160573171 cites W1571599379 @default.
• W2160573171 cites W1592664872 @default.
• W2160573171 cites W1605230984 @default.
• W2160573171 cites W1791206282 @default.
• W2160573171 cites W1969060932 @default.
• W2160573171 cites W1978758065 @default.
• W2160573171 cites W1982240588 @default.
• W2160573171 cites W1987672457 @default.
• W2160573171 cites W1999689304 @default.
• W2160573171 cites W2001790233 @default.
• W2160573171 cites W2026304756 @default.
• W2160573171 cites W2039011374 @default.
• W2160573171 cites W2046271685 @default.
• W2160573171 cites W2057215007 @default.
• W2160573171 cites W2059045334 @default.
• W2160573171 cites W2066044827 @default.
• W2160573171 cites W2085822471 @default.
• W2160573171 cites W2094221967 @default.
• W2160573171 cites W2096660754 @default.
• W2160573171 cites W2101359661 @default.
• W2160573171 cites W2103011221 @default.
• W2160573171 cites W2114303234 @default.
• W2160573171 cites W2127751922 @default.
• W2160573171 cites W2128253327 @default.
• W2160573171 cites W2141253976 @default.
• W2160573171 cites W2143758237 @default.
• W2160573171 cites W2144542552 @default.
• W2160573171 cites W2319972155 @default.
• W2160573171 cites W47967144 @default.
• W2160573171 doi "https://doi.org/10.3324/haematol.2009.018481" @default.
• W2160573171 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2930955" @default.
• W2160573171 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20378561" @default.
• W2160573171 hasPublicationYear "2010" @default.
• W2160573171 type Work @default.
• W2160573171 sameAs 2160573171 @default.
• W2160573171 citedByCount "160" @default.
• W2160573171 countsByYear W21605731712012 @default.
• W2160573171 countsByYear W21605731712013 @default.
• W2160573171 countsByYear W21605731712014 @default.
• W2160573171 countsByYear W21605731712015 @default.
• W2160573171 countsByYear W21605731712016 @default.
• W2160573171 countsByYear W21605731712017 @default.
• W2160573171 countsByYear W21605731712018 @default.
• W2160573171 countsByYear W21605731712019 @default.
• W2160573171 countsByYear W21605731712020 @default.
• W2160573171 countsByYear W21605731712021 @default.
• W2160573171 countsByYear W21605731712022 @default.
• W2160573171 countsByYear W21605731712023 @default.
• W2160573171 crossrefType "journal-article" @default.
• W2160573171 hasAuthorship W2160573171A5014727099 @default.
• W2160573171 hasAuthorship W2160573171A5024481322 @default.
• W2160573171 hasAuthorship W2160573171A5029042248 @default.
• W2160573171 hasAuthorship W2160573171A5036285321 @default.
• W2160573171 hasAuthorship W2160573171A5045374333 @default.
• W2160573171 hasAuthorship W2160573171A5052071966 @default.
• W2160573171 hasAuthorship W2160573171A5055178731 @default.
• W2160573171 hasAuthorship W2160573171A5064820449 @default.
• W2160573171 hasAuthorship W2160573171A5067324677 @default.
• W2160573171 hasAuthorship W2160573171A5081713373 @default.
• W2160573171 hasAuthorship W2160573171A5083135231 @default.
• W2160573171 hasBestOaLocation W21605731711 @default.
• W2160573171 hasConcept C126322002 @default.
• W2160573171 hasConcept C203014093 @default.
• W2160573171 hasConcept C2776995267 @default.
• W2160573171 hasConcept C2777761686 @default.
• W2160573171 hasConcept C2778461978 @default.
• W2160573171 hasConcept C2779338263 @default.
• W2160573171 hasConcept C2780126324 @default.
• W2160573171 hasConcept C71924100 @default.
• W2160573171 hasConcept C90924648 @default.
• W2160573171 hasConceptScore W2160573171C126322002 @default.
• W2160573171 hasConceptScore W2160573171C203014093 @default.
• W2160573171 hasConceptScore W2160573171C2776995267 @default.
• W2160573171 hasConceptScore W2160573171C2777761686 @default.
• W2160573171 hasConceptScore W2160573171C2778461978 @default.
• W2160573171 hasConceptScore W2160573171C2779338263 @default.
• W2160573171 hasConceptScore W2160573171C2780126324 @default.
• W2160573171 hasConceptScore W2160573171C71924100 @default.
• W2160573171 hasConceptScore W2160573171C90924648 @default.

• next